Opinion
Video
Author(s):
A panelist discusses how treatment decisions for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) involve careful consideration of patient preferences, long-term cost-effectiveness, and available financial assistance programs, balancing the higher upfront costs of newer therapies with their potential economic benefits from reduced recurrence rates and treatment frequency.
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.